Novocure reports Q3 financial results and announces the appointment of Christoph Brackmann as CFO, effective January 1, 2025. For more information, see our press releases: https://www.novocure.com/press-releases/
FDA approves Novocure’s treatment for metastatic non-small cell lung cancer (mNSCLC) for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with mNSCLC who progressed on or after a platinum-based regimen: https://www.novocure.com/fda-approves-novocures-optune-lua-for-the-treatment-of-metastatic-non-small-cell-lung-cancer/
Novocure will participate in the 2024 Wells Fargo Healthcare Conference on September 4. William Doyle, our Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors. Listen live on Sep 4 here: https://www.novocure.com/investor-relations/
This #WorldLungCancerDay, we thank the doctors, nurses, caregivers, patient organizations and all who support patients facing this difficult disease. #lungcancer
We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, up 11% compared to the same period in 2023. https://www.novocure.com/novocure-reports-second-quarter-2024-financial-results/
#earnings #NVCR
Today marks the 6th annual #GBMDay, when patients, caregivers, and advocates come together to support those living with #glioblastoma, remember those we have lost, and reaffirm our commitment to developing innovative treatments and, ultimately, a cure for this disease.